Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 17;14(10):101179. doi: 10.1016/j.tranon.2021.101179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Growth rates and predicted growth rates of Selinexor and Trametinib treated KRAS^mut mice. Mice were treated with Trametinib (1mg/kg) 5x/week, Selinexor (10mg/kg) [14,23] 3x/week. Data are separated by the individual independently established KRAS^mut PDX models. PHLC116: n = 5/arm; PHLC119: n = 5/arm; PHLC235: n = 5/arm; PHLC151: n = 2/Trametinib, n = 3/vehicle, Selinexor; PHLC239: n = 5/arm; PHLC256: n = 5/arm; PHLC344: n = 4/arm; PHLC110: n = 5/arm; PHLC314: n = 5/arm; PHLC426: n = 5/arm. Faded dashed lines in the background are the measured tumor growth patterns of individual mice. Dark lines represent predicted growth curves generated from the log linear mixed effects models [39]. KRAS mutation is indicated, along with prevalence of STK11/TP53 mutations.